

Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
64, 83-99

DOI: [10.1016/j.jacc.2014.05.003](https://doi.org/10.1016/j.jacc.2014.05.003)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Reply. Journal of the American College of Cardiology, 2014, 64, 2562.	1.2	1
2	Revisiting Arrhythmic Risk After Alcohol-Septal Ablation. JACC: Heart Failure, 2014, 2, 637-640.	1.9	11
3	Obstructive Sleep Apnea and Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 64, 2560-2562.	1.2	2
4	Surgical Septal Myectomy Versus Alcohol Septal Ablation. Circulation, 2014, 130, 1617-1624.	1.6	71
5	The implication of coronary artery malformations and congenital heart disease on cardiomyopathy. Progress in Pediatric Cardiology, 2014, 37, 19-22.	0.2	1
6	The 25-Year Genetic Era in Hypertrophic Cardiomyopathy: Revisited. Circulation: Cardiovascular Genetics, 2014, 7, 401-404.	5.1	15
7	Assessment of the 12-Lead ECG as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12-25 Years of Age). Circulation, 2014, 130, 1303-1334.	1.6	234
8	Assessment of the 12-Lead Electrocardiogram as a Screening Test for Detection of Cardiovascular Disease in Healthy General Populations of Young People (12-25 Years of Age). Journal of the American College of Cardiology, 2014, 64, 1479-1514.	1.2	180
9	P586 Modeling hypertrophic cardiomyopathy with human induced pluripotent stem cells. Cardiovascular Research, 2014, 103, S105.3-S105.	1.8	0
10	Reply. Journal of the American College of Cardiology, 2015, 66, 1846-1847.	1.2	3
11	Editorial: Cibenzoline for left ventricular outflow tract obstruction in tako-tsubo cardiomyopathy and hypertrophic cardiomyopathy. Journal of Cardiology Cases, 2015, 11, 158-159.	0.2	2
12	Role of augmented transferrin during the retraining for undeveloped left ventricle. Journal of Cellular and Molecular Medicine, 2015, 19, 2423-2431.	1.6	3
13	Contractility parameters of human β^2 -cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function. Science Advances, 2015, 1, e1500511.	4.7	102
14	Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug. Pharmacotherapy, 2015, 35, 1164-1172.	1.2	18
15	Clinical benefits of a specialised clinic for hypertrophic cardiomyopathy. Internal Medicine Journal, 2015, 45, 255-260.	0.5	5
16	<i>NOS1AP</i> Polymorphisms Modify QTc Interval Duration But Not Cardiac Arrest Risk in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2015, 26, 1346-1351.	0.8	4
17	Dynamic obstruction in hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2015, 30, 468-474.	0.8	6
18	The Importance of Genetic Testing in a Case of Sudden Death in Hypertrophic Cardiomyopathy due to Troponin I Mutation. Academic Forensic Pathology, 2015, 5, 155-160.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. <i>European Heart Journal</i> , 2015, 36, 1290-1296.	1.0	217
20	The Impact of Sports Cardiology on the Practice of Primary Care Sports Medicine. <i>Clinics in Sports Medicine</i> , 2015, 34, 381-390.	0.9	0
21	Historical Perspectives on the Implantable Cardioverter-Defibrillator and Prevention of Sudden Death in Hypertrophic Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 165-171.	0.7	4
22	The Role of Cardiovascular Magnetic Resonance in Sudden Death Risk Stratification in Hypertrophic Cardiomyopathy. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 187-193.	0.7	13
23	Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 116, 757-764.	0.7	148
24	Hypertrophic Cardiomyopathy: The Past, the Present, and the Future. , 2015, , 1-8.		4
25	A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. <i>Journal of Medical Genetics</i> , 2015, 52, 338-347.	1.5	41
26	The Spectrum of Epidemiology Underlying Sudden Cardiac Death. <i>Circulation Research</i> , 2015, 116, 1887-1906.	2.0	474
27	Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. <i>Heart</i> , 2015, 101, 1406-1411.	1.2	123
28	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. <i>Global Cardiology Science & Practice</i> , 2015, 2015, 16.	0.3	9
29	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on) Tj ETQq0 0 0 rgBT /Overlock 10 T 2015, 2015, 7.	0.3	11
30	Low Operative Mortality Achieved With Surgical Septal Myectomy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1307-1308.	1.2	146
31	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations. <i>Circulation</i> , 2015, 132, e256-61.	1.6	130
32	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis. <i>Circulation</i> , 2015, 132, e273-80.	1.6	296
33	Ultrastructural myocardial changes in seven cats with spontaneous hypertrophic cardiomyopathy. <i>Journal of Veterinary Cardiology</i> , 2015, 17, S220-S232.	0.3	9
34	Outcomes of Acute Myocardial Infarction in Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2015, 128, 879-887.e1.	0.6	18
35	Hypertrophic cardiomyopathy in man and cats. <i>Journal of Veterinary Cardiology</i> , 2015, 17, S6-S9.	0.3	35
36	Hypertrophic cardiomyopathy: Past, present and future. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 65-66.	2.3	6

#	ARTICLE	IF	CITATIONS
37	The 20 advances that have defined contemporary hypertrophic cardiomyopathy. Trends in Cardiovascular Medicine, 2015, 25, 54-64.	2.3	17
38	Editor-in-Chief's Picks From 2014: Part One. Journal of the American College of Cardiology, 2015, 65, 586-614.	1.2	0
39	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovascular Research, 2015, 105, 409-423.	1.8	66
40	Cardiac Cytoarchitecture. , 2015, , .		4
41	Importance and Feasibility of Creating Hypertrophic Cardiomyopathy Centers in Developing Countries: The Experience in India. American Journal of Cardiology, 2015, 116, 332-334.	0.7	18
42	Hypertrophic Cardiomyopathy, Athlete's Heart, or Both. Circulation: Cardiovascular Imaging, 2015, 8, e003312.	1.3	5
43	Sudden cardiac death in athletes. British Journal of Sports Medicine, 2015, 49, 1017-1023.	3.1	9
44	Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. American Journal of Cardiology, 2015, 116, 765-772.	0.7	46
45	Advanced Imaging of Athletes. Clinics in Sports Medicine, 2015, 34, 433-448.	0.9	3
46	Social determinants of health in the setting of hypertrophic cardiomyopathy. International Journal of Cardiology, 2015, 184, 743-749.	0.8	25
47	New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 1249-1254.	1.2	918
48	Sudden cardiac death in athletes. BMJ, The, 2015, 350, h1218-h1218.	3.0	23
49	The Dawn of a Better Day for Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 1929-1930.	1.2	10
50	Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Journal of the American College of Cardiology, 2015, 65, 1915-1928.	1.2	257
51	Mouse models for the study of postnatal cardiac hypertrophy. IJC Heart and Vasculature, 2015, 7, 131-140.	0.6	12
52	Atrial Fibrillation Ablation in Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 1485-1487.	1.2	28
53	Coronary Embolization in Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. American Journal of Cardiology, 2015, 115, 1318-1319.	0.7	8
54	Overview of Myocardial T1 Mapping Applications. Current Radiology Reports, 2015, 3, 1.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2343-2349.	1.2	141
56	Imaging in Deciphering Histological Substrates in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2015, 8, 1.	0.4	0
57	Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2015, 132, 292-298.	1.6	66
58	A focus on the prognosis and management of ischemic heart disease in patients without evidence of obstructive coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1031-1044.	0.6	3
59	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 116, 436-441.	0.7	62
60	Significance and Determinants of Cardiac Troponin I in Patients With Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015, 116, 1744-1751.	0.7	18
61	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2015, 8, 1014-1021.	1.6	67
62	Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy. <i>Circulation</i> , 2015, 132, 1013-1019.	1.6	19
63	Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 516-527.	1.3	37
64	Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2362-2371.	1.2	180
65	Surviving Malignant Hypertrophic Cardiomyopathy With all Major Complications in a Single Patient. <i>American Journal of Cardiology</i> , 2015, 115, 402-404.	0.7	2
67	Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells. , 0, , .		1
68	ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 188.	1.3	22
69	Mutation-Specific Phenotypes in hiPSC-Derived Cardiomyocytes Carrying Either Myosin-Binding Protein C Or β -Tropomyosin Mutation for Hypertrophic Cardiomyopathy. <i>Stem Cells International</i> , 2016, 1-16.	1.2	68
71	Cardiac Imaging in Hypertrophic Cardiomyopathy. , 0, , .		0
72	Pathophysiology of Heart Failure and an Overview of Therapies. , 2016, , 271-339.		4
73	Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. <i>PLoS ONE</i> , 2016, 11, e0146697.	1.1	72
74	Cardiac Troponin and Tropomyosin: Structural and Cellular Perspectives to Unveil the Hypertrophic Cardiomyopathy Phenotype. <i>Frontiers in Physiology</i> , 2016, 7, 429.	1.3	23

#	ARTICLE	IF	CITATIONS
75	Recent Advances in the Molecular Genetics of Familial Hypertrophic Cardiomyopathy in South Asian Descendants. <i>Frontiers in Physiology</i> , 2016, 7, 499.	1.3	13
76	Epigallocatechin-3-Gallate Accelerates Relaxation and Ca ²⁺ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice. <i>Frontiers in Physiology</i> , 2016, 7, 607.	1.3	16
77	The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 197.	1.3	50
78	Inherited Structural Heart Diseases With Potential Atrial Fibrillation Occurrence. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 242-252.	0.8	12
79	The Remarkable 50 Years of Imaging in HCM and How It Has Changed Diagnosis and Management. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 858-872.	2.3	43
80	The challenge of diagnosing hypertrophic cardiomyopathy in patients of African descent. <i>Heart</i> , 2016, 102, 1777-1778.	1.2	0
81	Significance of apical cavity obliteration in apical hypertrophic cardiomyopathy. <i>Heart</i> , 2016, 102, 1215-1220.	1.2	14
82	Comparison of hypertrophic cardiomyopathy in Afro-Caribbean versus white patients in the UK. <i>Heart</i> , 2016, 102, 1797-1804.	1.2	52
83	Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. <i>Open Heart</i> , 2016, 3, e000484.	0.9	48
84	Genetics and Genomics of Single-Gene Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2831-2849.	1.2	43
85	Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report. <i>BJPsych Open</i> , 2016, 2, 390-393.	0.3	4
86	Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H707-H712.	1.5	32
87	Current Cardiovascular Genetic Counseling. <i>Current Genetic Medicine Reports</i> , 2016, 4, 142-146.	1.9	0
88	Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 1808-1814.	0.7	12
89	Clinical utility of natriuretic peptides and troponins in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2016, 218, 252-258.	0.8	21
90	Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?. <i>JACC: Heart Failure</i> , 2016, 4, 689-697.	1.9	49
91	How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality. <i>JAMA Cardiology</i> , 2016, 1, 98.	3.0	191
92	Athlete Screening for Cardiomyopathies: Recent Insights and Latest Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0

#	ARTICLE	IF	CITATIONS
93	Unique cause of right hemispheric syndrome: Embolism of myocardium after open septal myectomy. <i>Neuroradiology Journal</i> , 2016, 29, 110-114.	0.6	4
94	Molecular autopsy in victims of inherited arrhythmias. <i>Journal of Arrhythmia</i> , 2016, 32, 359-365.	0.5	46
95	Troponins, intrinsic disorder, and cardiomyopathy. <i>Biological Chemistry</i> , 2016, 397, 731-751.	1.2	18
96	Pulmonary hypertension in hypertrophic cardiomyopathy: a forgotten marker in the identification of candidates to surgical myectomy?. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 611-612.	0.5	5
97	Nuclear Imaging for Assessment of Myocardial Perfusion, Metabolism, and Innervation in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2016, 9, 1.	0.4	1
98	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	0.6	754
99	Current perspectives in hypertrophic cardiomyopathy with the focus on patients in the Finnish population: a review. <i>Annals of Medicine</i> , 2016, 48, 496-508.	1.5	6
100	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. <i>European Journal of Heart Failure</i> , 2016, 18, 1106-1118.	2.9	101
101	Value of Genetic Testing for the Prediction of Long-Term Outcome in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 881-887.	0.7	32
102	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
103	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
104	Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio. <i>Atherosclerosis</i> , 2016, 253, 225-236.	0.4	23
105	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2413-2422.	3.3	20
106	Is It Possible to Predict the Onset of "Heart Failure" in Hypertrophic Cardiomyopathy?. <i>Circulation Journal</i> , 2016, 80, 67-68.	0.7	0
107	Heart Failure Progression in Hypertrophic Cardiomyopathy—Possible Insights From Cardiopulmonary Exercise Testing " ". <i>Circulation Journal</i> , 2016, 80, 2204-2211.	0.7	41
108	LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators —. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1403-1406.	2.3	23
109	Saving Lives One at a Time. <i>JAMA Cardiology</i> , 2016, 1, 387.	3.0	5
110	A Discussion of Contemporary Nomenclature, Diagnosis, Imaging, and Management of Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 118, 1897-1907.	0.7	15

#	ARTICLE	IF	CITATIONS
111	The clinical use of stress echocardiography in non-ischæmic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1191-1229.	0.5	300
112	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. <i>Pediatric Critical Care Medicine</i> , 2016, 17, S16-S19.	0.2	7
113	Learn from Your Elders: Why We Need to Increase Exposure to Geriatrics in Medical Training. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 452-453.	1.3	1
114	Fatal Cardiac Arrest Associated with Concomitant Bisoprolol and Verapamil Overdose. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 451-452.	1.3	3
115	The Father of Septal Myectomy for Obstructive HCM, Who Also Had HCM. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2900-2903.	1.2	9
116	Left ventricular mechanical dispersion is associated with nonsustained ventricular tachycardia in hypertrophic cardiomyopathy. <i>Annals of Medicine</i> , 2016, 48, 417-427.	1.5	19
117	Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy. <i>Biology of Sex Differences</i> , 2016, 7, 22.	1.8	18
118	First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2811-2818.	1.2	69
119	Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline. <i>Current Cardiology Reports</i> , 2016, 18, 70.	1.3	7
120	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1399-1409.	1.2	142
121	Evaluation and Management of Concomitant Hypertrophic Obstructive Cardiomyopathy and Valvular Aortic Stenosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 17.	0.4	13
122	Surgical Ventricular Septal Myectomy in the Developing World. <i>American Journal of Cardiology</i> , 2016, 117, 874-877.	0.7	5
123	Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives. <i>Europace</i> , 2016, 18, 638-647.	0.7	30
124	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016, 117, 1151-1159.	0.7	25
125	Enlarged left atrium and sudden death risk in hypertrophic cardiomyopathy patients with or without atrial fibrillation. <i>Journal of Cardiology</i> , 2016, 68, 478-484.	0.8	25
126	Nonobstructive Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2016, 91, 277-278.	1.4	2
127	Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	54
128	Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management. <i>Radiographics</i> , 2016, 36, 335-354.	1.4	83

#	ARTICLE	IF	CITATIONS
129	Commentary on "Hypertrophic Cardiomyopathy from A to Z" with Response from Dr Baxi and Colleagues. <i>Radiographics</i> , 2016, 36, 355-357.	1.4	0
130	MYBPH acts as modifier of cardiac hypertrophy in hypertrophic cardiomyopathy (HCM) patients. <i>Human Genetics</i> , 2016, 135, 477-483.	1.8	26
131	Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2016, 13, 1155-1165.	0.3	66
132	What Do Patients With Hypertrophic Cardiomyopathy Die from?. <i>American Journal of Cardiology</i> , 2016, 117, 434-435.	0.7	46
133	Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. <i>Circulation</i> , 2016, 133, 62-73.	1.6	135
134	Impact of exercise-induced mitral regurgitation on hypertrophic cardiomyopathy outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1110-1117.	0.5	15
135	Misconceptions and Facts About Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2016, 129, 148-152.	0.6	17
136	Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017, 35, 1916-1922.	2.0	14
137	A Long Term Follow-up Study of Carriers of Hypertrophic Cardiomyopathy Mutations. <i>Heart Lung and Circulation</i> , 2017, 26, 18-24.	0.2	4
138	Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 249-254.	0.6	9
140	Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 35-46.	1.1	10
141	Why we need more septal myectomy surgeons: An emerging recognition. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1681-1685.	0.4	48
142	The Clinical Use of Stress Echocardiography in Non-Ischaemic Heart Disease: Recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 101-138.	1.2	207
143	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 231, 115-119.	0.8	30
144	Pregnancy and Congenital Heart Disease. <i>Congenital Heart Disease in Adolescents and Adults</i> , 2017, , .	0.2	3
145	Saving More Lives —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 774-776.	1.2	2
146	An Asymptomatic Septal Perforator Coronary Artery "Left Ventricle Fistula Following Myectomy in a Patient With Obstructive Hypertrophic Cardiomyopathy. <i>Angiology</i> , 2017, 68, 835-836.	0.8	0
148	Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm. <i>Journal of the American College of Cardiology</i> , 2017, 69, 761-773.	1.2	252

#	ARTICLE	IF	CITATIONS
149	Mechanism of Progressive Heart Failure and Significance of Pulmonary Hypertension in Obstructive Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, e003689.	1.6	43
150	Exercise Training In Athletes With Heart Disease. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 121-129.	1.6	9
151	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. <i>Heart Rhythm</i> , 2017, 14, e55-e96.	0.3	204
152	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, 22, e12447.		52
153	Epidemiology of ventricular tachyarrhythmia. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2017, 28, 143-148.	0.3	7
154	Titin-Truncating Variants Increase the Risk of Cardiovascular Death in Patients With Hypertrophic Cardiomyopathy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1292-1297.	0.8	18
155	Cardiomyopathy and anaesthesia. <i>BJA Education</i> , 2017, 17, 363-369.	0.6	8
156	Burden of Recurrent and Ancestral Mutations in Families With Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	18
157	Next-generation sequencing identifies pathogenic and modifier mutations in a consanguineous Chinese family with hypertrophic cardiomyopathy. <i>Medicine (United States)</i> , 2017, 96, e7010.	0.4	6
158	Helical distribution of hypertrophy in patients with hypertrophic cardiomyopathy: prevalence and clinical implications. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1771-1780.	0.7	7
159	Human heart disease: lessons from human pluripotent stem cell-derived cardiomyocytes. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3711-3739.	2.4	51
160	Coronary Microcirculatory Dysfunction in Human Cardiomyopathies. <i>Cardiology in Review</i> , 2017, 25, 165-178.	0.6	12
161	LAMP2 shines a light on cardiomyopathy in an athlete. <i>HeartRhythm Case Reports</i> , 2017, 3, 172-176.	0.2	6
162	Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene. <i>Stem Cell Research</i> , 2017, 20, 88-90.	0.3	11
163	Cardiopulmonary Exercise Test in Hypertrophic Cardiomyopathy. <i>Annals of the American Thoracic Society</i> , 2017, 14, S102-S109.	1.5	34
164	Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathyâ€. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, 1112-1118.	0.6	23
165	Life-long tailoring of management for patients with hypertrophic cardiomyopathy. <i>Netherlands Heart Journal</i> , 2017, 25, 186-199.	0.3	24
166	Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2017, 120, 2256-2264.	0.7	45

#	ARTICLE	IF	CITATIONS
167	Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2017, 136, 2420-2436.	1.6	183
168	Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 112, 83-90.	0.9	3
169	Hypertrophic Cardiomyopathy. <i>Circulation Research</i> , 2017, 121, 749-770.	2.0	790
170	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
171	The MOGE(S) classification for cardiomyopathies: current status and future outlook. <i>Heart Failure Reviews</i> , 2017, 22, 743-752.	1.7	40
172	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 407.	1.2	1
173	Impact of peak provoked left ventricular outflow tract gradients on clinical outcomes in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2017, 243, 290-295.	0.8	17
174	Role of Exercise Testing in Hypertrophic Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1374-1386.	2.3	68
175	Generalidades de las miocardiopatías. <i>Miocardiopatía hipertrófica</i> . <i>Medicine</i> , 2017, 12, 2548-2560.	0.0	0
176	Co-inheritance of mutations associated with arrhythmogenic cardiomyopathy and hypertrophic cardiomyopathy. <i>European Journal of Human Genetics</i> , 2017, 25, 1165-1169.	1.4	10
177	How to Image Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	1.3	49
178	Myofilament protein dynamics modulate EAD formation in human hypertrophic cardiomyopathy. <i>Progress in Biophysics and Molecular Biology</i> , 2017, 130, 418-428.	1.4	10
179	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 102-112.	6.1	18
180	Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2017, 119, 100-105.	0.7	40
181	Nonobstructive Hypertrophic Cardiomyopathy Out of the Shadows: Known from the Beginning but Largely Ignored Until Now. <i>American Journal of Medicine</i> , 2017, 130, 119-123.	0.6	17
182	Imaging methods in cardiomyopathies. <i>Cor Et Vasa</i> , 2017, 59, e157-e162.	0.1	2
183	The Role of Cardiac Myosin Binding Protein C3 in Hypertrophic Cardiomyopathy—Progress and Novel Therapeutic Opportunities. <i>Journal of Cellular Physiology</i> , 2017, 232, 1650-1659.	2.0	13
184	Cardiac magnetic resonance imaging: Which information is useful for the arrhythmologist?. <i>World Journal of Cardiology</i> , 2017, 9, 773.	0.5	4

#	ARTICLE	IF	CITATIONS
185	Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 354-360.	0.3	5
186	Recent Advances in Hypertrophic Cardiomyopathy: A System Review. , 0, , .		2
187	Modulating Beta-Cardiac Myosin Function at the Molecular and Tissue Levels. <i>Frontiers in Physiology</i> , 2016, 7, 659.	1.3	16
188	Investigations into the Sarcomeric Protein and Ca ²⁺ -Regulation Abnormalities Underlying Hypertrophic Cardiomyopathy in Cats (<i>Felix catus</i>). <i>Frontiers in Physiology</i> , 2017, 8, 348.	1.3	15
189	Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model. <i>Frontiers in Physiology</i> , 2017, 8, 558.	1.3	11
190	Conservative versus invasive treatment in hypertrophic obstructive cardiomyopathy: an echocardiography study. <i>Bratislava Medical Journal</i> , 2017, 117, 562-570.	0.4	0
191	Implantable Cardioverter-Defibrillators in Inherited Arrhythmia Syndromes. , 2017, , 566-578.		0
192	Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2018, 131, e235-e239.	0.6	35
193	CaMKII-mediated phosphorylation of RyR2 plays a crucial role in aberrant Ca ²⁺ release as an arrhythmogenic substrate in cardiac troponin T-related familial hypertrophic cardiomyopathy. <i>Biochemical and Biophysical Research Communications</i> , 2018, 496, 1250-1256.	1.0	24
194	Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	47
195	Cardiovascular magnetic resonance imaging in heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 237-248.	0.6	6
196	Characterization of hypertrophic cardiomyopathy according to global, regional, and multi-layer longitudinal strain analysis, and prediction of sudden cardiac death. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 1091-1098.	0.7	15
198	Sex Differences in Cardiac Arrhythmias. , 2018, , 247-269.		0
200	Electrocardiography scar quantification correlates with scar size of hypertrophic cardiomyopathy seen by multidetector computed tomography. <i>Clinical Cardiology</i> , 2018, 41, 837-842.	0.7	7
201	A Case of Multiple Ventricular Gradients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1829-1832.	0.6	1
202	International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: The REVEAL Study. <i>Journal of Veterinary Internal Medicine</i> , 2018, 32, 930-943.	0.6	91
203	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005820.	2.1	50
204	Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2018, 6, 353-363.	1.9	105

#	ARTICLE	IF	CITATIONS
205	Prognosis of adult obstructive hypertrophic cardiomyopathy patients with different morphological types after surgical myectomy. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 310-317.	0.6	11
206	Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 396-401.	0.5	23
207	Rest and Stress Longitudinal Systolic Left Ventricular Mechanics in Hypertrophic Cardiomyopathy: Implications for Prognostication. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 578-586.	1.2	12
208	Baseline fragmented <sc>QRS</sc> increases the risk of major arrhythmic events in hypertrophic cardiomyopathy: Systematic review and meta-analysis. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12533.	0.5	15
209	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004124.	1.6	103
210	B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2018, 15, 1484-1490.	0.3	18
211	Morphological Determinants of Obstructive Hypertrophic Cardiomyopathy Obtained Using Echocardiography. <i>International Heart Journal</i> , 2018, 59, 339-346.	0.5	6
212	Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2018, 131, 837-841.	0.6	50
213	Sex Differences in Cardiac Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005680.	2.1	52
214	Familial Hypertrophic Cardiomyopathy - Identification of cause and risk stratification through exome sequencing. <i>Gene</i> , 2018, 660, 151-156.	1.0	8
215	Standardized Goal-Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2018, 31, 791-798.	1.2	22
216	Outcomes in Patients With Hypertrophic Cardiomyopathy Awaiting Heart Transplantation. <i>Circulation: Heart Failure</i> , 2018, 11, e004378.	1.6	30
217	Prevalence and Impact of Coexistent Bicuspid Aortic Valve in Hypertrophic Cardiomyopathy. <i>Heart Lung and Circulation</i> , 2018, 27, 33-40.	0.2	11
218	Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction: Expecting the Unexpected. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 467-477.	0.6	12
219	The role of human urotensin-II in patients with hypertrophic cardiomyopathy. <i>Journal of Immunoassay and Immunochemistry</i> , 2018, 39, 150-162.	0.5	8
220	Cardiac actin changes in the actomyosin interface have different effects on myosin duty ratio. <i>Biochemistry and Cell Biology</i> , 2018, 96, 26-31.	0.9	8
221	Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Medicine</i> , 2018, 131, 200.e1-200.e8.	0.6	31
222	Exercise-Induced Arrhythmias. , 2018, , 615-622.		0

#	ARTICLE	IF	CITATIONS
223	Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. , 2018, , 829-839.		0
224	Role of echocardiography in the diagnosis and management of hypertrophic cardiomyopathy. Heart, 2018, 104, 261-273.	1.2	10
225	Hypertrophic Cardiomyopathy and Related Conditions. , 2018, , 118-142.		0
226	Update on the Diagnosis and Management of Hypertrophic Cardiomyopathy. Heart Lung and Circulation, 2018, 27, 276-279.	0.2	8
227	Structural destabilization of tropomyosin induced by the cardiomyopathy-linked mutation R21H. Protein Science, 2018, 27, 498-508.	3.1	8
228	Patient understanding of disease and the use and outcome of implantable cardioverter defibrillators in hypertrophic cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 57-64.	0.5	0
229	Clinical presentations of hypertrophic cardiomyopathy and implications for therapy. Global Cardiology Science & Practice, 2018, 2018, 19.	0.3	3
230	Cardiac magnetic resonance imaging in the evaluation of patients with hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2018, 2018, 22.	0.3	18
231	Modeling Cardiac Hemodynamic Response During Exercise in Health and Hypertrophic Cardiomyopathy. , 2018, 2018, 4532-4535.		0
232	Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 3087-3094.	1.2	85
233	Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy: What has Changed in The Guidelines?. Arquivos Brasileiros De Cardiologia, 2018, 110, 524-531.	0.3	1
234	Prevention of Sudden Death in Hypertrophic Cardiomyopathy. Arquivos Brasileiros De Cardiologia, 2018, 110, 532-533.	0.3	0
235	Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1939-1946.	0.7	15
236	Stress Echocardiography: the Role in Assessing Valvular Heart Diseases. Current Cardiovascular Imaging Reports, 2018, 11, 1.	0.4	1
237	Prevalence and Prognostic Significance of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 122, 1932-1938.	0.7	18
238	Outcomes of patients with hypertrophic cardiomyopathy and acute myocardial infarction: a propensity score-matched, 15-year nationwide population-based study in Asia. BMJ Open, 2018, 8, e019741.	0.8	4
239	Long-Term Outcomes of Acute Myocardial Infarction in Patients With Hypertrophic Cardiomyopathy. Angiology, 2018, 69, 900-908.	0.8	6
240	Late Gadolinium Enhancement for Prediction of Mutation-Positive Hypertrophic Cardiomyopathy on the Basis of Panel-Wide Sequencing. Circulation Journal, 2018, 82, 1139-1148.	0.7	8

#	ARTICLE	IF	CITATIONS
241	Genetic variation at the long noncoding RNA H19 gene is associated with the risk of hypertrophic cardiomyopathy. <i>Epigenomics</i> , 2018, 10, 865-873.	1.0	23
242	Association of cardiac myosin binding protein-C with the ryanodine receptor channel: putative retrograde regulation?. <i>Journal of Cell Science</i> , 2018, 131, .	1.2	9
243	Mitral valve abnormalities in hypertrophic cardiomyopathy: a primary expression of the disease? Getting closer to the answer. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1107-1108.	0.5	6
244	Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 419-429.	1.2	138
245	Development of a 3-D printing-based cardiac surgical simulation curriculum to teach septal myectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 1139-1148.e3.	0.4	15
246	High Signal Intensity on T2-Weighted Cardiovascular Magnetic Resonance Imaging Predicts Life-Threatening Arrhythmic Events in Hypertrophic Cardiomyopathy Patients. <i>Circulation Journal</i> , 2018, 82, 1062-1069.	0.7	23
247	LGE-CMR-derived texture features reflect poor prognosis in hypertrophic cardiomyopathy patients with systolic dysfunction: preliminary results. <i>European Radiology</i> , 2018, 28, 4615-4624.	2.3	56
248	CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2018, 39, 3879-3892.	1.0	176
249	Guidelines for Heart Disease Screening in Schools (JCS 2016/JSPCCS 2016)â€• Digest Version â€•. <i>Circulation Journal</i> , 2018, 82, 2385-2444.	0.7	20
250	Routine Papillary Muscle Realignment and Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2018, 106, 670-675.	0.7	23
252	Clinical Course and Management of Hypertrophic Cardiomyopathy. <i>New England Journal of Medicine</i> , 2018, 379, 655-668.	13.9	562
253	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2018, 271, 125-131.	0.8	19
254	Long-term outcome of catheter ablation for atrial fibrillation in patients with apical hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 951-957.	0.8	15
255	Mid-term outcomes of biventricular obstruction and left ventricular outflow tract obstruction after surgery correction in child and adolescent patients with hypertrophic cardiomyopathy. <i>PLoS ONE</i> , 2018, 13, e0192218.	1.1	6
256	Predictors of future onset of atrial fibrillation in hypertrophic cardiomyopathy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 591-600.	0.7	11
257	Disclosure of diagnosis to at-risk relatives by individuals diagnosed with hypertrophic cardiomyopathy (HCM). <i>Journal of Community Genetics</i> , 2019, 10, 207-217.	0.5	7
258	Multimodality Imaging of Danon Disease in a Patient with a Novel LAMP2 Mutation. <i>Case</i> , 2019, 3, 235-238.	0.1	0
259	Non-invasive prediction of genotype positive phenotype negative in hypertrophic cardiomyopathy by 3D modern shape analysis. <i>Experimental Physiology</i> , 2019, 104, 1688-1700.	0.9	11

#	ARTICLE	IF	CITATIONS
260	Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 2167-2175.	0.7	3
261	Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue. <i>Frontiers in Physiology</i> , 2019, 10, 239.	1.3	9
262	Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches. <i>Current Cardiology Reports</i> , 2019, 21, 75.	1.3	14
263	Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil. <i>Journal of Biological Chemistry</i> , 2019, 294, 17314-17325.	1.6	18
265	Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2019, 297, 75-82.	0.8	3
266	Native T1 time and extracellular volume fraction in differentiation of normal myocardium from non-ischemic dilated and hypertrophic cardiomyopathy myocardium: A systematic review and meta-analysis. <i>IJC Heart and Vasculature</i> , 2019, 25, 100422.	0.6	6
267	Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002460.	1.6	267
268	Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 932-938.	0.5	20
269	A feline orthologue of the human MYH7 c.5647G>A (p.(Glu1883Lys)) variant causes hypertrophic cardiomyopathy in a Domestic Shorthair cat. <i>European Journal of Human Genetics</i> , 2019, 27, 1724-1730.	1.4	19
270	Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. <i>JAMA Cardiology</i> , 2019, 4, 644.	3.0	222
271	Advanced Evolution of Pathogenesis Concepts in Cardiomyopathies. <i>Journal of Clinical Medicine</i> , 2019, 8, 520.	1.0	14
272	Identification of biomarkers correlated with hypertrophic cardiomyopathy with co-expression analysis. <i>Journal of Cellular Physiology</i> , 2019, 234, 21999-22008.	2.0	37
273	Prevention of Sudden Death Related to Sport: The Science of Basic Life Support“from Theory to Practice. <i>Journal of Clinical Medicine</i> , 2019, 8, 556.	1.0	7
274	Microvascular Dysfunction in Hypertrophic Cardiomyopathy. <i>Current Cardiovascular Imaging Reports</i> , 2019, 12, 1.	0.4	0
276	Epidemiology of Heart Failure. <i>Cardiovascular Medicine</i> , 2019, , 3-36.	0.0	1
277	Induced Pluripotent Stem Cell“Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 394-403.	1.1	28
278	Midventricular obstructive hypertrophic cardiomyopathy with apical aneurysm: An important subtype of arrhythmogenic cardiomyopathy. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12638.	0.5	9
279	High T2-weighted signal intensity is associated with myocardial deformation in hypertrophic cardiomyopathy. <i>Scientific Reports</i> , 2019, 9, 2644.	1.6	4

#	ARTICLE	IF	CITATIONS
280	Separation of HCM and LQT Cardiac Diseases with Machine Learning of Ca ²⁺ Transient Profiles. <i>Methods of Information in Medicine</i> , 2019, 58, 167-178.	0.7	9
281	Sudden Cardiac Death: Can We Solve the Puzzle?. <i>Journal of Cardiac Critical Care TSS</i> , 2019, 3, 077-084.	0.0	0
283	Fibrosis and Ventricular Arrhythmogenesis. <i>Cardiac Electrophysiology Clinics</i> , 2019, 11, 551-562.	0.7	9
284	Hypertrophic cardiomyopathy: genetics and clinical perspectives. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, S388-S415.	0.7	63
286	Can epinephrine therapy be detrimental to patients with hypertrophic cardiomyopathy with hypotension or cardiac arrest? A systematic review. <i>European Journal of Emergency Medicine</i> , 2019, 26, 150-157.	0.5	3
287	Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. <i>Scientific Reports</i> , 2019, 9, 18152.	1.6	13
288	A <i>de novo</i> mutation of <i>SMYD1</i> (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 532-539.	1.4	19
289	Novel phenotype-genotype correlations of hypertrophic cardiomyopathy caused by mutation in β -actin and myosin-binding protein genes in three unrelated Chinese families. <i>Journal of Cardiology</i> , 2019, 73, 438-444.	0.8	6
290	Advanced Heart Failure Management and Transplantation. <i>Cardiology Clinics</i> , 2019, 37, 105-111.	0.9	7
291	Arrhythmias in Hypertrophic Cardiomyopathy. , 2019, , 925-941.		0
292	Cardiac Myosin-Binding Protein C—From Bench to Improved Diagnosis of Acute Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 221-230.	1.3	14
293	Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 1.	0.7	66
294	LncRNA <i>MIAT</i> regulates fibrosis in hypertrophic cardiomyopathy (HCM) by mediating the expression of <i>miR-29a-3p</i> . <i>Journal of Cellular Biochemistry</i> , 2019, 120, 7265-7275.	1.2	24
295	Sudden Cardiac Death Risk Assessment. , 2019, , 145-155.		0
296	Gradient variability in hypertrophic cardiomyopathy: New insights from computer-assisted, high fidelity, rest and exercise hemodynamic analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, E37-E43.	0.7	2
297	Hypertrophic Cardiomyopathy: The Past, the Present, and the Future. , 2019, , 1-8.		0
298	A Premature Termination Codon Mutation in <i>MYBPC3</i> Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. <i>Circulation</i> , 2019, 139, 799-811.	1.6	91
299	Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. <i>Heart and Vessels</i> , 2019, 34, 527-537.	0.5	8

#	ARTICLE	IF	CITATIONS
300	Sudden Cardiac Death and Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. <i>Heart Lung and Circulation</i> , 2019, 28, 146-154.	0.2	20
301	Risk stratification in hypertrophic cardiomyopathy. <i>Herz</i> , 2020, 45, 50-64.	0.4	7
302	Heart Failure as a Consequence of Hypertrophic Cardiomyopathy. , 2020, , 311-321.e6.		0
303	Elevated lymphatic vessel density measured by Lyve-1 expression in areas of replacement fibrosis in the ventricular septum of patients with hypertrophic obstructive cardiomyopathy (HOCM). <i>Heart and Vessels</i> , 2020, 35, 78-85.	0.5	9
304	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1821-1831.	0.8	15
305	Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. <i>Heart and Vessels</i> , 2020, 35, 876-885.	0.5	2
306	Establishing a new human hypertrophic cardiomyopathy-specific model using human embryonic stem cells. <i>Experimental Cell Research</i> , 2020, 387, 111736.	1.2	5
307	MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction. <i>Radiology</i> , 2020, 294, 275-286.	3.6	67
308	Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy. <i>Pharmacological Research</i> , 2020, 160, 105176.	3.1	12
309	Heart failure from ATTRwt amyloid cardiomyopathy is associated with poor prognosis. <i>ESC Heart Failure</i> , 2020, 7, 3919-3928.	1.4	17
311	Novel Therapeutic Effects of Pterosin B on Ang II-Induced Cardiomyocyte Hypertrophy. <i>Molecules</i> , 2020, 25, 5279.	1.7	11
312	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2020, 76, 3022-3055.	1.2	394
313	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, e159-e240.	1.2	364
314	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2020, 142, e558-e631.	1.6	263
315	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. <i>Circulation</i> , 2020, 142, e533-e557.	1.6	181
316	Preoperative Statin Use Is Associated With Less Postoperative Atrial Fibrillation After Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2020, 33, 713-719.	0.4	3
317	RAD-Deficient Human Cardiomyocytes Develop Hypertrophic Cardiomyopathy Phenotypes Due to Calcium Dysregulation. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 585879.	1.8	8
318	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. <i>PLoS ONE</i> , 2020, 15, e0236814.	1.1	1

#	ARTICLE	IF	CITATIONS
319	Variable Penetrance in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 560-562.	1.2	13
320	Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 1341-1350.	0.5	35
321	The Advantages of New Multimodality Imaging in Choosing the Optimal Management Strategy for Patients with Hypertrophic Cardiomyopathy. <i>Diagnostics</i> , 2020, 10, 719.	1.3	0
322	Late gadolinium enhancement location assessed by magnetic resonance and arrhythmogenic risk in hypertrophic cardiomyopathy. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 615-621.	0.2	4
323	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 516.	0.7	33
324	Abnormalities in sodium current and calcium homeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. <i>Cardiovascular Research</i> , 2020, 116, 1585-1599.	1.8	40
325	Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 359-366.	0.7	6
326	New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 99-109.	0.2	2
327	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. <i>Journal of Clinical Medicine</i> , 2020, 9, 1636.	1.0	15
328	Are all non-sustained ventricular tachycardia the same in hypertrophic cardiomyopathy risk stratification for sudden cardiac death?. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2099-2100.	0.8	0
329	Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study. <i>British Journal of Sports Medicine</i> , 2020, 54, 1008-1012.	3.1	30
330	Prevalence and determinants of elevated D-dimer in patients with hypertrophic cardiomyopathy. <i>Biomarkers in Medicine</i> , 2020, 14, 131-140.	0.6	5
331	Prognostic Implication of First-Degree Atrioventricular Block in Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e015064.	1.6	12
332	Emergence of endocardium/epicardium flow gradient as novel risk biomarker in patients with hypertrophic cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2020, 26, 100467.	0.6	1
333	Sexual dimorphism in cardiac transcriptome associated with a troponin C murine model of hypertrophic cardiomyopathy. <i>Physiological Reports</i> , 2020, 8, e14396.	0.7	7
334	Design of the SILICOFM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. <i>Clinical Cardiology</i> , 2020, 43, 430-440.	0.7	15
335	Diagnostic yield and long-term outcome of nonischemic sudden cardiac arrest survivors and their relatives: Results from a tertiary referral center. <i>Heart Rhythm</i> , 2020, 17, 1679-1686.	0.3	6
336	PRKAG2 Glycogen Storage Disease Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 198-200.	1.2	2

#	ARTICLE	IF	CITATIONS
337	Long-Term Performance of Right Ventricular Implantable Cardioverter-Defibrillator Leads in Arrhythmogenic Right Ventricular Cardiomyopathy and Hypertrophic Cardiomyopathy. <i>International Heart Journal</i> , 2020, 61, 39-45.	0.5	3
338	RNA Splicing Defects in Hypertrophic Cardiomyopathy: Implications for Diagnosis and Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1329.	1.8	15
339	Phenotypes of hypertrophic cardiomyopathy: genetics, clinics, and modular imaging. <i>Heart Failure Reviews</i> , 2021, 26, 1023-1036.	1.7	17
340	Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: A nationwide population-based cohort study. <i>PLoS ONE</i> , 2020, 15, e0227012.	1.1	28
341	Perioperative Echocardiography in the Adult With Congenital Heart Disease. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 1292-1308.	0.6	1
342	Impact of Septal Myectomy Volume on Mitral-Valve Replacement Rate in Hypertrophic Cardiomyopathy Patients. <i>Cardiology</i> , 2020, 145, 161-167.	0.6	11
343	Novas perspectivas no tratamento farmacolÃ³gico da miocardiopatia hipertrÃ³fica. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 99-109.	0.2	3
344	Hypertrophic cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2020, 27, 100503.	0.6	35
345	Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy: The Utility of Myocardial Strain Based on Cardiac ^{sc>MR} Tissue Tracking. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 51-60.	1.9	8
346	Relation of atrial electromechanical delay to PÃ©wave dispersion on surface ECG using vector velocity imaging in patients with hypertrophic cardiomyopathy. <i>Annals of Noninvasive Electrocardiology</i> , 2021, 26, e12801.	0.5	4
348	Effects of pimobendan on left atrial transport function in cats. <i>Journal of Veterinary Internal Medicine</i> , 2021, 35, 10-21.	0.6	7
349	Hypertrophic Cardiomyopathy in Pregnancy. <i>Cardiology Clinics</i> , 2021, 39, 143-150.	0.9	7
350	Cardiovascular Magnetic Resonance in Heritable Cardiomyopathies. <i>Heart Failure Clinics</i> , 2021, 17, 25-39.	1.0	2
351	Phenotypic variation and targeted therapy of hypertrophic cardiomyopathy using genetic animal models. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 20-31.	2.3	8
352	The relation between sarcomere energetics and the rate of isometric tension relaxation in healthy and diseased cardiac muscle. <i>Journal of Muscle Research and Cell Motility</i> , 2021, 42, 47-57.	0.9	19
353	Impact of body mass index on left atrial dimension in HOCM patients. <i>Open Medicine (Poland)</i> , 2021, 16, 207-216.	0.6	2
354	Hypertrophic Cardiomyopathy-Anesthesia Considerations for Septal Myectomy. , 2021, , 233-242.		0
355	AS and HCM. , 2021, , 163-167.		0

#	ARTICLE	IF	CITATIONS
357	Systolic anterior motion in hypertrophic cardiomyopathy: a fluid-structure interaction computational model. <i>Theoretical and Computational Fluid Dynamics</i> , 2021, 35, 381-396.	0.9	7
358	Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy. , 0, , .		0
359	Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan—Report From a National Registry of Clinical Personal Records. <i>Circulation Reports</i> , 2021, 3, 142-152.	0.4	7
360	Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 45.	1.6	18
361	The Wait is Over: The 2020 American Heart Association/American College of Cardiology (AHA/ACC) Hypertrophic Cardiomyopathy Guidelines Have Arrived. <i>Heart Lung and Circulation</i> , 2021, 30, 465-468.	0.2	1
362	Transcriptome Sequencing of Patients With Hypertrophic Cardiomyopathy Reveals Novel Splice-Altering Variants in <i>MYBPC3</i> . <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003202.	1.6	18
363	Future bradyarrhythmia in patients with hypertrophic cardiomyopathy. <i>IJC Heart and Vasculature</i> , 2021, 33, 100735.	0.6	1
364	Cardiac MRI in cardiomyopathies. <i>Future Cardiology</i> , 2022, 18, 51-65.	0.5	5
365	Clinical prediction of genotypes in hypertrophic cardiomyopathy: A systematic review. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13593.	1.7	7
366	Identification of Potential miRNA-mRNA Regulatory Network Contributing to Hypertrophic Cardiomyopathy (HCM). <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 660372.	1.1	8
367	Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 264-269.	0.5	1
368	Cardiovascular magnetic resonance detects microvascular dysfunction in a mouse model of hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 63.	1.6	3
369	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. <i>Current Heart Failure Reports</i> , 2021, 18, 169-179.	1.3	19
370	An Unusual Case of Shock in an Octogenarian. <i>Annals of Geriatric Medicine and Research</i> , 2021, 25, 129-132.	0.7	0
371	Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2021, 18, 1012-1023.	0.3	44
372	Novel pathogenic variant of MYBPC3 responsible for hypertrophic cardiomyopathy. <i>Cardiology in the Young</i> , 2021, , 1-6.	0.4	0
373	Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy in the Elderly. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1477-1481.	0.7	9
374	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.4	33

#	ARTICLE	IF	CITATIONS
375	Whole-exome sequencing reveals MYH7 p.R671C mutation in three different phenotypes of familial hypertrophic cardiomyopathy. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1002.	0.8	6
376	Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 92.	1.6	26
377	Beware of regression of electrocardiographic abnormalities on detraining – It may not always mean –athlete's heart™. <i>Revista Portuguesa De Cardiologia</i> , 2021, , .	0.2	0
378	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. <i>Russian Journal of Cardiology</i> , 2021, 26, 4594.	0.4	89
379	Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics. <i>Pediatric Cardiology</i> , 2021, , 1.	0.6	2
380	Hypertrophic Cardiomyopathy Diagnosed on Point-of-Care Echocardiogram in an Elderly Patient With Syncope. <i>Cureus</i> , 2021, 13, e17008.	0.2	2
381	A radiomic approach to predict myocardial fibrosis on coronary CT angiography in hypertrophic cardiomyopathy. <i>International Journal of Cardiology</i> , 2021, 337, 113-118.	0.8	10
382	Ouabain worsens diastolic sarcomere length in myocytes from a cardiomyopathy mouse model. <i>European Journal of Pharmacology</i> , 2021, 904, 174170.	1.7	1
383	Pathogenic Mechanisms of Hypertrophic Cardiomyopathy beyond Sarcomere Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8933.	1.8	20
384	Hypertrophic Cardiomyopathy in the General Population. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1111-1113.	1.2	0
385	Left Atrial Strain and Function in Pediatric Hypertrophic Cardiomyopathy. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 996-1006.	1.2	11
386	Hypertrophic cardiomyopathy in children. <i>Asian Cardiovascular and Thoracic Annals</i> , 2022, 30, 92-97.	0.2	6
387	Automatic machine learning based on native T1 mapping can identify myocardial fibrosis in patients with hypertrophic cardiomyopathy. <i>European Radiology</i> , 2021, , 1.	2.3	6
388	Anticoagulation in cardiomyopathy: unravelling the hidden threat and challenging the threat individually. <i>ESC Heart Failure</i> , 2021, 8, 4737-4750.	1.4	7
389	Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based) Tj ETQq0 0,0 rgBT /Qverlock 10	0.7	5
390	Commentary: Atrial Fibrillation, Statin, and Septal Myectomy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 720-721.	0.4	0
391	How Cardiac Cytoarchitecture Can Go Wrong: Hypertrophic Cardiomyopathy as a Paradigm for Genetic Disease of the Heart. , 2015, , 227-243.		1
392	Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. <i>Heart Rhythm</i> , 2020, 17, 1658-1663.	0.3	14

#	ARTICLE	IF	CITATIONS
393	Use of Intraoperative Dobutamine Stress Echocardiography on Outcomes of Septal Myectomy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, 33, 1037-1042.	0.4	6
394	Diastolic Vortex Alterations With Reducing Left Ventricular Volume: An In Vitro Study. <i>Journal of Biomechanical Engineering</i> , 2020, 142, .	0.6	6
395	Effectiveness of a patient-specific 3-dimensional printed model in Septal Myectomy of hypertrophic cardiomyopathy. <i>Pakistan Journal of Medical Sciences</i> , 2020, 36, 1678-1682.	0.3	4
396	Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. <i>Journal of Animal Science and Technology</i> , 2015, 2, E1-E7.	0.8	6
397	Contextualizing Genetics for Regional Heart Failure Care. <i>Current Cardiology Reviews</i> , 2016, 12, 231-242.	0.6	8
398	Hemodynamic Instability in Heart Failure Intensifies Age-Dependent Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 63-84.	1.2	6
399	Hypertrophic Obstructive Cardiomyopathy. <i>Deutsches A&#x0308;rztblatt International</i> , 2019, 116, 47-53.	0.6	18
400	Cardiomiopatia HipertrÃ³fica â€“ RevisÃ£o. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 927-935.	0.3	9
401	Magnetic Resonance Imaging of Non-ischemic Cardiomyopathies: A Pictorial Essay. <i>Journal of Clinical Imaging Science</i> , 2015, 5, 37.	0.4	11
402	Left atrial volume during stress is associated with increased risk of arrhythmias in patients with hypertrophic cardiomyopathy. <i>Journal of Cardiovascular Echography</i> , 2019, 29, 1.	0.1	9
403	Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 107, 257-265.	0.3	6
404	Electrocardiographic Diagnosis of Hypertrophic Cardiomyopathy in the Pre- and Post-Diagnostic Phases in Children and Adolescents. <i>Circulation Journal</i> , 2021, 86, 118-127.	0.7	5
405	Non-pharmaceutical Interventions for Hypertrophic Cardiomyopathy: A Mini Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 695247.	1.1	1
407	AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. <i>Journal of Biological Engineering</i> , 2021, 15, 24.	2.0	0
408	Case of the patient with non-obstructive hypertrophic cardiomyopathy regarding to European guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>Srce I Krvni Sudovi</i> , 2014, 33, 251-253.	0.1	0
409	Impact of Genomics and Personalised Medicine on Current Practice of Clinical Cardiology. <i>Journal of Cardiology & Current Research</i> , 2014, 1, .	0.1	0
410	Stress Echocardiography in Hypertrophic Cardiomyopathy. , 2015, , 551-568.		0
411	Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. , 2016, , 149-181.		1

#	ARTICLE	IF	CITATIONS
412	Hypertrophic Cardiomyopathy (HCM). , 2017, , 49-53.		1
413	Pregnancy in Hypertrophic Cardiomyopathy. Congenital Heart Disease in Adolescents and Adults, 2017, , 155-164.	0.2	0
414	Contribution of Surgical Procedures Including Insertions of Implants, Stents, and Pacemakers to Longevity. Journal of Gerontology & Geriatric Research, 2017, 06, .	0.1	0
415	The role of cardiovascular magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Part I. Vnitřní Lékařství, 2017, 63, 194-198.	0.1	0
416	Catheter Ablation of Atrial Fibrillation in Chronic Heart Failure: A Contemporary Review. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2648-2656.	0.2	0
417	Septal Ablation in Obstructive Hypertrophic Cardiomyopathy (oHCM). Arquivos Brasileiros De Cardiologia, 2019, 112, 439-440.	0.3	0
418	Prognostic implications of different clinical profiles in hypertrophic cardiomyopathy. Minerva Cardiology and Angiology, 2022, 70, .	0.4	1
419	Comparative Study of Functional Changes in Heart Mitochondria in Two Modes of Epinephrine Exposure Modeling Myocardial Injury in Rats. Bulletin of Experimental Biology and Medicine, 2021, 171, 727-731.	0.3	3
421	Familial Hypertrophic Cardiomyopathy: Late Potentials and Other Prognostic Markers. Cureus, 2020, 12, e6530.	0.2	1
422	Use of peripheral nerve blocks in perioperative management of cases with hypertrophic cardiomyopathy undergoing lower limb orthopedic surgeries. Anesthesia: Essays and Researches, 2020, 14, 277.	0.2	1
423	Apical hypertrophic cardiomyopathy: contemporary view on the prevalence, clinical profile, diagnostic and treatment (review of literature). Učeny Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2021, 28, 17-22.	0.0	0
424	Exercise Echocardiography following Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy. Thoracic and Cardiovascular Surgeon, 2020, , .	0.4	1
425	Late gadolinium enhancement location assessed by magnetic resonance and arrhythmogenic risk in hypertrophic cardiomyopathy. Revista Portuguesa De Cardiologia (English Edition), 2020, 39, 615-621.	0.2	1
426	A One Health Approach to Hypertrophic Cardiomyopathy. Yale Journal of Biology and Medicine, 2017, 90, 433-448.	0.2	12
427	Beware of regression of electrocardiographic abnormalities on detraining “It may not always mean “athlete's heart”. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 801.e1-801.e6.	0.2	0
429	Prevalence and Impact of Atrial Fibrillation in a Cohort of Patients with Hypertrophic Cardiomyopathy in Ireland. Journal of Atrial Fibrillation, 2020, 13, 2337.	0.5	0
430	The impact of cardiopulmonary exercise-derived scoring on prediction of cardio-cerebral outcome in hypertrophic cardiomyopathy. PLoS ONE, 2022, 17, e0259638.	1.1	3
431	Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era. Frontiers in Cardiovascular Medicine, 2021, 8, 765876.	1.1	7

#	ARTICLE	IF	CITATIONS
432	Dysfunctional Network and Mutation Genes of Hypertrophic Cardiomyopathy. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-11.	1.1	4
433	Artificial intelligence study on left ventricular function among normal individuals, hypertrophic cardiomyopathy and dilated cardiomyopathy patients using 1.5T cardiac cine MR images obtained by SSFP sequence. <i>British Journal of Radiology</i> , 2022, 95, 20201060.	1.0	3
435	Surgical treatment of hypertrophic obstructive cardiomyopathy in relatively elderly patients: Short- and long-term outcomes. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	0.6	2
436	Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathy—An Analysis from the SILICOFCM Database. <i>Medicina (Lithuania)</i> , 2022, 58, 314.	0.8	10
437	Anatomical-MRI Correlations in Adults and Children with Hypertrophic Cardiomyopathy. <i>Diagnostics</i> , 2022, 12, 489.	1.3	1
438	Emergency department utilization in patients with hypertrophic cardiomyopathy: a nationwide population-based study. <i>Scientific Reports</i> , 2022, 12, 3534.	1.6	1
439	Altered intercellular communication and extracellular matrix signaling as a potential disease mechanism in human hypertrophic cardiomyopathy. <i>Scientific Reports</i> , 2022, 12, 5211.	1.6	10
440	MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers. <i>Heart Failure Reviews</i> , 2022, 27, 2211-2221.	1.7	9
441	Use of Photovoice to Explore Pediatric Patients with Hypertrophic Cardiomyopathy and their Parents' Perceptions of a Heart-Healthy Lifestyle. <i>Journal of the American Heart Association</i> , 2022, 11, e023572.	1.6	3
442	Oxidative Stress Markers in Hypertrophic Cardiomyopathy. <i>Medicina (Lithuania)</i> , 2022, 58, 31.	0.8	9
443	Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2573-2579.	1.2	17
444	Automated Classification of Left Ventricular Hypertrophy on Cardiac MRI. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 4151.	1.3	4
445	Catheter ablation of ventricular tachycardia in dilated-â€‘phase hypertrophic cardiomyopathy: Substrate characterization and ablation outcome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 773-785.	0.5	3
455	Electro-fluid-mechanics of the heart. <i>Journal of Fluid Mechanics</i> , 2022, 941, .	1.4	15
456	Right Ventricular Enlargement and Dysfunction Are Associated With Increased All-Cause Mortality in Hypertrophic Cardiomyopathy. <i>Mayo Clinic Proceedings</i> , 2022, , .	1.4	0
457	Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. <i>American Journal of Cardiology</i> , 2022, 174, 120-125.	0.7	2
458	Usefulness of Tissue Tracking by Cardiac Magnetic Resonance to Predict Events in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, 174, 126-135.	0.7	2
459	Single-cell transcriptomics provides insights into hypertrophic cardiomyopathy. <i>Cell Reports</i> , 2022, 39, 110809.	2.9	20

#	ARTICLE	IF	CITATIONS
460	PARADOXICAL PROLONGATION OF QT INTERVAL DURING EXERCISE IN PATIENTS WITH HCM: CELLULAR MECHANISMS AND IMPLICATIONS FOR DIASTOLIC FUNCTION. <i>European Heart Journal Open</i> , 0, , .	0.9	1
461	Systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: a narrative review. <i>Journal of Thoracic Disease</i> , 2022, 14, 2309-2325.	0.6	11
462	Temporal Changes in Cardiac Morphology and Its Relationship with Clinical Characteristics and Outcomes in Patients with Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2022, 176, 125-131.	0.7	1
463	Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 533-560.	1.2	46
464	Model Embraced Electromechanical Coupling Time for Estimation of Heart Failure in Patients With Hypertrophic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
465	Drug loss from Paclitaxel-Coated Balloons During Preparation, Insertion and Inflation for Angioplasty: A Laboratory Investigation. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 1186-1197.	0.9	5
466	Augmented risk of dementia in hypertrophic cardiomyopathy: A propensity score matching analysis using the nationwide cohort. <i>PLoS ONE</i> , 2022, 17, e0269911.	1.1	0
467	Exercise Stress Testing in Athletes. <i>Clinics in Sports Medicine</i> , 2022, 41, 441-454.	0.9	2
468	Novel molecular insights and potential approaches for targeting hypertrophic cardiomyopathy: Focus on coronary modulators. <i>Vascular Pharmacology</i> , 2022, 145, 107003.	1.0	1
469	Circulatory System (Cardiovascular and Lymphatic Systems). , 2022, , 323-383.		1
470	Pathophysiology of heart failure and an overview of therapies. , 2022, , 149-221.		1
472	Human-Induced Pluripotent Stem Cell-â€œDerived Cardiomyocyte Model for <i>TNNT2</i> 160E-Induced Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, .	1.6	5
473	Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States. <i>Journal of Clinical Medicine</i> , 2022, 11, 3898.	1.0	0
474	Treatment of Severe Left Ventricular Outflow Tract Obstruction and Mitral Regurgitation With Alcohol Septal Ablation. <i>Case</i> , 2022, 6, 387-391.	0.1	2
475	Transcriptome Profile Identifies Actin as an Essential Regulator of Cardiac Myosin Binding Protein C3 Hypertrophic Cardiomyopathy in a Zebrafish Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8840.	1.8	1
476	Comparison of Cardiac Wall Thicknesses and Coronary Artery Obstructions Between Deaths Resulting From Acute Myocardial Infarction and Deaths From Other Causes. <i>Medeniyet Medical Journal</i> , 0, , .	0.4	0
478	Cardiovascular causes of complex breathlessness. , 2022, , 153-172.		0
479	Generation of an induced pluripotent stem cell line (ZJULLi003-A) from a hypertrophic cardiomyopathy patient carrying MYH7/c.4384G>Â mutation. <i>Stem Cell Research</i> , 2022, 64, 102883.	0.3	0

#	ARTICLE	IF	CITATIONS
480	The initial experience of left bundle branch area pacing in patients with hypertrophic cardiomyopathy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 1065-1074.	0.5	8
481	Demographic and Regional Trends of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	4
482	Different characteristics of apical aneurysm in hypertrophic cardiomyopathy are related to difference in long-term prognosis. <i>International Journal of Cardiology</i> , 2023, 370, 287-293.	0.8	1
483	Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 529-537.	0.7	11
484	RNA-seq profiling reveals different pathways between remodelled vessels and myocardium in Hypertrophic Cardiomyopathy. <i>Microcirculation</i> , 0, , .	1.0	2
485	Successful pregnancy and delivery in a young-onset hypertrophic cardiomyopathy patient with a novel doublet-base substitution in the MYH7 gene. <i>Journal of Cardiology Cases</i> , 2023, 27, 8-11.	0.2	0
487	Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. <i>Cardiology and Therapy</i> , 2022, 11, 491-507.	1.1	10
488	Liquid-liquid phase separation, membrane-less organelles, and biomolecular condensates in cardiovascular disease. , 2023, , 663-679.		0
490	Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. <i>Heart International</i> , 2022, 16, 91.	0.4	6
491	Hypertrophic Obstructive Cardiomyopathy with SAM Phenomenon: A Case Report and Literature Review. <i>Cardiology and Cardiovascular Medicine</i> , 2022, 06, .	0.1	0
492	Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis. <i>JACC: Heart Failure</i> , 2023, 11, 30-41.	1.9	7
493	Risk factors, clinical features, and outcomes of patients with hypertrophic cardiomyopathy complicated by ischemic stroke: A single-center retrospective study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
494	A General Framework for Exploring Ethical and Legal Issues in Sports Medicine. <i>Journal of the American Board of Family Medicine</i> , 2022, 35, 1230-1238.	0.8	2
495	Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction. <i>Heart</i> , 2023, 109, 771-778.	1.2	7
496	A Case Report on the Atypical Presentation of Hypertrophic Cardiomyopathy (HOCM) in a 19-Year-Old Female. <i>Cureus</i> , 2022, , .	0.2	0
497	An Integrated Algorithm for Differentiating Hypertrophic Cardiomyopathy From Hypertensive Heart Disease. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	0
498	Prognostic Implication of Mitral Valve Disease and Its Progression in East Asian Patients With Hypertrophic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	3
499	Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy. <i>Gene Therapy</i> , 2023, 30, 520-527.	2.3	3

#	ARTICLE	IF	CITATIONS
500	Left atrial strain assessment using cardiac computed tomography in patients with hypertrophic cardiomyopathy. Japanese Journal of Radiology, 0, , .	1.0	0
501	Cardiomyopathies in Children: Genetics, Pathomechanisms and Therapeutic Strategies. , 0, , .		0
502	Reversible Apical Hypertrophy in a Young Competitive Athlete with Familiar Hypertrophic Cardiomyopathy. American Journal of Case Reports, 0, 24, .	0.3	0
503	A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy. Southern Medical Journal, 2022, 115, 926-929.	0.3	3
504	Impact of coronary artery revascularization on long-term outcome in hypertrophic cardiomyopathy patients: a nationwide population-based cohort study. Scientific Reports, 2023, 13, .	1.6	1
512	Circulatory System. , 2023, , 223-267.		0
526	Stress Echocardiography in Hypertrophic Cardiomyopathy. , 2023, , 459-481.		0
541	RNA binding proteins in cardiovascular development and disease. Current Topics in Developmental Biology, 2024, , 51-119.	1.0	0